How to Help Your Patients Find Vestura in Stock: A Provider's Guide

Since the discontinuation of Vestura by Teva Pharmaceuticals, providers across the country have seen an uptick in patient calls, portal messages, and appointment requests from patients who are confused, worried, or struggling to find their birth control. This guide gives you the clinical language and practical tools to resolve these situations quickly.

Understanding What Patients Are Experiencing

When patients say "Vestura is unavailable," they typically mean one of three things:

1. Their regular pharmacy no longer stocks Vestura (brand discontinued)
2. They were auto-switched to a different generic (often Gianvi or Loryna) and are experiencing unexpected side effects
3. They can't find their preferred drospirenone/EE generic in stock at pharmacies near them

Each scenario requires a slightly different response from the clinical team.

Scenario 1: Patient's Pharmacy No Longer Carries Vestura

Recommended response:

• Issue a new prescription for drospirenone 3 mg / ethinyl estradiol 0.02 mg, specifying Nikki or Loryna by name (most widely available)
• Reassure the patient that the drug itself hasn't changed — only the brand packaging
• Advise the patient to start the new generic at the beginning of the next pack cycle, not mid-pack

Scenario 2: Patient Was Auto-Switched and Is Having Side Effects

This is the most clinically nuanced scenario. Some patients report mood changes, acne flares, or spotting after switching to a different drospirenone/EE generic. While the active ingredients are identical, differences in inactive ingredients, dissolution profiles, or patient expectations can play a role.

Steps:

1. Allow 2-3 cycles on the new generic before assessing — many adjustment symptoms resolve within this window
2. If symptoms persist, switch to Nikki (most similar inactive ingredient profile to Vestura) or to brand-name Yaz (dispense as written)
3. Document the clinical rationale for brand-name dispensing if prior authorization is required by the patient's insurer

Scenario 3: Patient Can't Find the Preferred Generic in Stock

While drospirenone/EE 0.02mg generics are not in an active FDA shortage, localized stocking gaps can occur depending on pharmacy chain and region.

Recommend these options to patients:

• Use medfinder — calls local pharmacies on the patient's behalf to find which ones have the medication in stock, and texts results to the patient
• Mail-order pharmacy — especially beneficial for 90-day supplies and patients in underserved areas
• Telehealth contraception platforms — Nurx, Pandia Health, and Hims/Hers can prescribe and ship drospirenone/EE directly

Scripted Communication for Patient Portal Messages

Here is a template message your care team can adapt for patient portal responses:

"Hi [Patient Name], the Vestura brand was discontinued by the manufacturer — this was not a safety issue. The same active hormones are still available under different names. We have updated your prescription to [Nikki/Loryna/drospirenone-EE]. Please take this to any pharmacy. The medication works identically to Vestura. Please allow 1-2 cycles for adjustment. Contact us if you have persistent new symptoms."

When to Consider a Different Contraceptive Class

Some patients will use this transition as an opportunity to reassess their contraceptive method. Situations where a different class may be appropriate include:

• Elevated VTE risk (personal or family history of clots) — consider progestin-only pill or non-hormonal options
• Patient intolerance to all drospirenone generics — consider a different progestin class (norethindrone, levonorgestrel, norgestimate)
• Desire for long-acting contraception — consider IUD or implant

Key Takeaways for Your Practice

• Vestura discontinued = brand packaging change, not a safety issue
• Nikki is the most similar in inactive ingredients to Vestura; Loryna is most widely available
• Allow 2-3 cycles before concluding a new generic isn't working
• Direct patients to medfinder to find in-stock pharmacies near them

For a deeper clinical overview, see Vestura Discontinuation: What Providers and Prescribers Need to Know in 2026.